Evidence map›Paper›PMID 40128500›Full record

ReviewDrugs2025

Classic Psychedelics for the Treatment of Depression: Potential Benefits and Challenges.

Sharmin Ghaznavi, Sarah G Richter

Abstract readReview
PubMed Publisher
In one paragraph

Review in Drugs, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Current perspectives on psychedelic treatments in Europe.The Lancet regional health. Europe · 2026
    Review
  3. Effects of Psilocin and Psilocybin on Human 5-HTPharmaceuticals (Basel, Switzerland) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Sharmin GhaznaviDepartment of Psychiatry, Center for the Neuroscience of Psychedelics, Massachusetts General Hospital, 149 13th St, Charlestown, MA, 02129, USA. sghaznavi@mgh.harvard.edu.ORCID http://orcid.org/0000-0002-3773-9760
Sarah G RichterDepartment of Psychiatry, Center for the Neuroscience of Psychedelics, Massachusetts General Hospital, 149 13th St, Charlestown, MA, 02129, USA.ORCID http://orcid.org/0000-0003-0653-1024

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There has been a recent resurgence in research on psychedelics as therapeutic agents for psychiatric conditions. This leading article outlines the studies to date of classic psychedelic treatments for treatment-resistant depression and major depression, including psilocybin, ayahuasca, dimethyltryptamine (DMT), and O-methyl-bufotenine (5-Me-O DMT). We discuss the potential of expanding treatment options for depression based on the data available, as well as the difficulties and limitations of research on psychedelics that make assessing that potential more challenging.

Indexed as

Depressive Disorder, Treatment-ResistantHallucinogensMajor Depressive DisorderAntidepressive AgentsBanisteriopsisHumansN,N-DimethyltryptaminePsilocybinAntidepressive AgentsHallucinogensN,N-DimethyltryptaminePsilocybin

Identifiers

PMID40128500

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.